Proarrhythmia risk prediction using human induced pluripotent stem cell-derived cardiomyocytes
Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) are expected to become a useful tool for proarrhythmia risk prediction in the non-clinical drug development phase. Several features including electrophysiological properties, ion channel expression profile and drug responses were...
Saved in:
Main Authors: | Daiju Yamazaki (Author), Takashi Kitaguchi (Author), Masakazu Ishimura (Author), Tomohiko Taniguchi (Author), Atsuhiro Yamanishi (Author), Daisuke Saji (Author), Etsushi Takahashi (Author), Masao Oguchi (Author), Yuta Moriyama (Author), Sanae Maeda (Author), Kaori Miyamoto (Author), Kaoru Morimura (Author), Hiroki Ohnaka (Author), Hiroyuki Tashibu (Author), Yuko Sekino (Author), Norimasa Miyamoto (Author), Yasunari Kanda (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2018-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Assessment of Testing Methods for Drug-Induced Repolarization Delay and Arrhythmias in an iPS Cell-Derived Cardiomyocyte Sheet: Multi-site Validation Study
by: Yuji Nakamura, et al.
Published: (2014) -
Transgenic Rabbit Models in Proarrhythmia Research
by: István Baczkó, et al.
Published: (2020) -
Development of torsadogenic risk assessment using human induced pluripotent stem cell-derived cardiomyocytes: Japan iPS Cardiac Safety Assessment (JiCSA) update
by: Yasunari Kanda, et al.
Published: (2018) -
Torsadogenic potential of a novel remyelinating drug clemastine for multiple sclerosis assessed in the rabbit proarrhythmia model
by: Satoshi Kawakami, et al.
Published: (2020) -
Proarrhythmia associated with antiarrhythmic drugs: a comprehensive disproportionality analysis of the FDA adverse event reporting system
by: Feifei Wang, et al.
Published: (2023)